menu search

Paxmedica’s research on low dose suramin for autism spectrum disorder accepted for publication

TARRYTOWN, N.Y. , Oct. 26, 2023 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (Nasdaq: PXMD) a clinical-stage biopharmaceutical company, is excited...

October 26, 2023, 5:51 pm

Credit suisse chairman: "i am truly sorry"

Credit Suisse's chairman told a room full of shareholders that he was "truly sorry" the Swiss bank was not able to get back on track at its final annu...

April 4, 2023, 4:43 am

Cellectis publishes manuscript in frontiers bioengineering and biotechnology unveiling efficient multitool/multiplex gene engineering combining talen® and tale base editors (tale-be)

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology c...

November 10, 2022, 7:48 am

Mind medicine shares up as phase 2b studies continue on medical lsd

Mind Medicine Inc. MNMD, -7.06% (MindMed) shares rose 10% in premarket trades on Thursday after the company said patient dosing in its Phase 2b trial ...

September 8, 2022, 8:08 am


Search within

Pages Search Results: